Neurocrine Biosciences, Inc.


Neurocrine Biosciences is a San Diego based biotechnology company focused on neurologic and endocrine related disorders. Neurocrine developed and markets INGREZZA™, a novel, once-daily, selective VMAT2 inhibitor approved by the FDA on 11-Apr-2017 for the treatment of adults with tardive dyskinesia and is currently commercialized by Neurocrine in the U.S. INGREZZA™ is under investigation for the treatment of Tourette Syndrome.

Exhibitor Level: 
Bronze Level
Booth Number: 
Exhibitor Type: 
Biotechnology Pharmaceuticals